Article information
Full text is only aviable in PDF
References
[1.]
G.S. Firestein.
Evolving concepts of rheumatoid arthritis.
Nature, 423 (2003), pp. 356-361
[2.]
J.S. Smolen, D. Aletaha, J. Grisar, K. Redlich, G. Steiner, O. Wagner.
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?.
Arthritis Res Ther, 10 (2008), pp. 208
[3.]
J.S. Smolen, D. Aletaha, M. Koeller, M.H. Weisman, P. Emery.
New therapies for treatment of rheumatoid arthritis.
Lancet, 370 (2007), pp. 1861-1874
[4.]
W. de Jager, B.J. Prakken, J.W. Bijlsma, W. Kuis, G.T. Rijkers.
Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies.
J Immunol Methods, 300 (2005), pp. 124-135
[5.]
W. Hueber, B.H. Tomooka, X. Zhao.
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines.
Ann Rheum Dis, 66 (2007), pp. 712-719
[6.]
L. Boiardi, P. Macchioni, R. Meliconi, L. Pulsatelli, A. Facchini, C. Salvarani.
Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate.
Clin Exp Rheumatol, 17 (1999), pp. 419-425
[7.]
S.W. Syversen, G.L. Goll, E.A. Haavardsholm, P. Boyesen, T. Lea, T.K. Kvien.
A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients.
Arthritis Res Ther, 10 (2008), pp. R28
[8.]
S. Fabre, A.M. Dupuy, N. Dossat, et al.
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
Clin Exp Immunol, 153 (2008), pp. 188-195
[9.]
C.A. Hitchon, P. Alex, L.B. Erdile, et al.
A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
J Rheumatol, 31 (2004), pp. 2336-2346
[10.]
I. Rioja, F.J. Hughes, C.H. Sharp, et al.
Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colonystimulating factor.
Arthritis Rheum, 58 (2008), pp. 2257-2267
[11.]
J.M. Davis, K.L. Knutson, M.A. Strausbauch, et al.
Serum Cytokine Levels Determined by Multiplex Assays and Clinical Characteristics in Patients with Rheumatoid Arthritis.
Arthritis Rheum, 56 (2007), pp. S270
[12.]
J.A. van Roon, K. Jacobs, S. Verstappen, J. Bijlsma, F. Lafeber.
Reduction of serum interleukin 7 levels upon methotrexate therapy in early rheumatoid arthritis correlates with disease suppression.
Ann Rheum Dis, 67 (2008), pp. 1054-1055
[13.]
J.A. van Roon, S.A. Hartgring, M. Wenting-van Wijk, et al.
Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis.
Ann Rheum Dis, 66 (2007), pp. 664-669
[14.]
I. Rioja, K.A. Bush, J.B. Buckton, M.C. Dickson, P.F. Life.
Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment.
Clin Exp Immunol, 137 (2004), pp. 65-73
[16.]
Y. Yagil, C. Yagil.
Pharmacogenomic considerations for immunosuppressive therapy.
Pharmacogenomics, 4 (2003), pp. 309-319
[17.]
K.G. Faag, G.G. Teng, N.M. Patker, et al.
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum (Arthritis Care Res), 59 (2008), pp. 762-784
[18.]
N.J. Olsen, T.M. Stein.
New drugs for rheumatoid arthritis.
N Engl J Med, 350 (2004), pp. 2167-2179
[19.]
P. Ranganthan, S. Eisen, W. Yokoyama, H. McLeod.
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?.
Ann Rheum Dis, 62 (2003), pp. 4-9
[20.]
K. Payne, W. Newman, E. Fargher, et al.
TPMT testing in rheumatology: Any better than routine monitoring?.
Rheumatology, 46 (2007), pp. 727-729
[22.]
D. Cattaneo, S. Baldelli, N. Perico.
Pharmacogenetics of immunosuppression: Progress, pitfalls, and promises.
Am J Transplantation, 8 (2008), pp. 1374-1383
[23.]
M. Seitz, M. Zwicker, P.M. Villiger.
Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American College of Rheumatology response groups to methotrexate.
J Rheumatol, 30 (2003), pp. 28-35
Copyright © 2009. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
